12.22.2018 Issue 153

Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Jobs Round-up
Job of the Week Latest Jobs from the Jobs Portal

Executive Director, Health Technology Assessment (HTA) Statistics

Reporting to the Senior Vice President and Head of BARDS, the incumbent has centralized responsibility and decision making authority for all biostatistics activities in support of HTA Dossiers and submissions.

Researcher - HEOR

Executive Director, Health Technology Assessment (HTA) Statistics (U.K.)

Health Economics and Outcomes Associate Consultant

Research Data Assistant or Research Data Coordinator-PS8373

Online Instructor in Applied Health Economics

Report: Federal Judge Rules ACA Unconstitutional After Penalty Removed

Article: Value-Based Pricing and Reimbursement Remains Mostly Promise

Dubois: Challenges Remain for Integrating Personalized Medicine, Value Frameworks

FDA Moves on Biosimilars, Outlines New Plans

Industry Spotlight

Conferences Webinars
Reimbursement and Contracting
    January 23-24, Philadelphia, Pennsylvania

Data Analytics and Decisions
    January 23-24, Philadelphia, Pennsylvania

Special Therapies 2019
    January 24-25, Las Vegas, Nevada

The Payer and Provider Ecosystem Evolution
    January 27-30, San Diego, California

Identifying Medical Conditions in Administrative Claims Data: Validation and Machine Learning
    January 8

How to Leverage Real World Data to Achieve Faster Insights for Better Adverse Event Detection and Reporting
    January 16

HEOR & RWE: Global Sourcing Strategies and Best Practices
    January 24

Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs and Biologics

Blockchain: Transformational Change for Pharma?

Benchmarking Market Access Strategies for High-Cost Drugs and Biologics

HTA in Europe: Key Success Factors for Positive HTA Recommendations

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)

From Patent to Patient: Analyzing Access to Innovative Cancer Drugs

Transitioning Payment Models: Fee-for-Service to Value-Based Care

How Health Plans and Providers Can Collaborate to Improve Care Transitions and Reduce Hospital Readmissions

Generating Consensus and Trust for Quality Measurement to Support Value-Based Care

Special Thanks to Our Partners:
               Evidera   HealthCore  
      University of FL   Xcenda  OM1    Parexel   Jefferson
      Dymaxium   Precision Xtract    Pharmerit    eMax Health
      Sciformix   Evidence Partners    ICON    Truven